Prospective ctDNA Testing in Large B-Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) are aggressive lymphomas commonly treated with first-line immunochemotherapy. Some patients experience disease progression or relapse despite treatment. PET/CT is used to assess treatment response, but it may not identify small amounts of residual lymphoma. Circulating tumor DNA (ctDNA) consists of tumor-derived DNA fragments detectable in blood. This prospective observational study will use PhasED-seq to assess plasma ctDNA before, during, and after first-line therapy in approximately 100 patients with newly diagnosed DLBCL or HGBL. The primary objective is to evaluate the association between ctDNA status approximately 8 weeks after completion of first-line therapy and subsequent progression-free survival. Additional analyses will examine overall survival, earlier ctDNA findings, and baseline tumor molecular subtypes. PET/CT findings will provide complementary information for exploratory analyses. The findings may inform future studies of response-adapted treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Potwierdzony rozpoznaniem chłoniaka z dużych komórek B lub chłoniaka wysokozłośliwego z komórek B
- •Planowane standardowe leczenie przeciwnowotworowe zawierające určony lek i chemioterapię
- •Brak planowanego leczenia podtrzymującego po zakończeniu głównego leczenia
- •Dobrowolna zgodę na udział w badaniu
✗ Disqualifies
- •Chłoniak rozwinięty z powolnie postępującego chłoniaka
- •Chłoniak z dużych komórek B u pacjentów z wirusem HIV
- •Poprzednia chemioterapia, terapia celowana lub immunoterapia tego samego typu nowotworu
- •Jednoczesne występowanie innego raka
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 16, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Beijing TongRen Hospital
Beijing, China
Peking University People's Hospital
Beijing, China
Trial contact
Jin Lu, MD.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/17/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.